Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.

Weder, C; Baltariu, G M; Wyler, K A; Gober, H-J; Lienert, C; Schluep, M; Radü, E W; De Libero, G; Kappos, L; Duda, P W

Weder, C; Baltariu, G M; Wyler, K A; Gober, H-J; Lienert, C; Schluep, M; Radü, E W; De Libero, G; Kappos, L; Duda, P W.

Affiliation

Weder C; Department of Neurology, University Hospital, Basle, Switzerland.

Eur J Neurol ; 12(11): 869-78, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16241976

Subject(s)

Cytokines/metabolism; Immune Tolerance; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Peptides/therapeutic use; Adult; Biomarkers/analysis; Glatiramer Acetate; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting/immunology; Prospective Studies; Th2 Cells; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Cytokines / Multiple Sclerosis, Relapsing-Remitting / Immune Tolerance Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Humans / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2005 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links